http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Sucampo (SCMP) Reports FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation
-
Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation
-
Sucampo Pharmaceuticals Announces Presentation at Deutsche Bank’s 25th Annual Leveraged Finance Conference
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
-
Sucampo Pharmaceuticals Appoints Alex Driggs as General Counsel
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference
-
UPDATE: Cancer Prevention Pharmaceuticals Secures $9.5M in Additional Funding from Sucampo (SCMP) Following Phase 3 Trial Progress
-
Cancer Prevention Pharmaceuticals Receives $9.5 Million in Additional Funding from Sucampo Following Phase 3 Trial Progress
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Wells Fargo Healthcare Conference
-
Sucampo Reports Second Quarter 2017 Financial Results
-
Sucampo Announces Second Quarter 2017 Earnings Call
-
Sucampo Pharma (SCMP) Names Karen Smith to Board of Directors
-
Dr. Karen Smith Joins Sucampo’s Board of Directors
-
Sucampo Pharma (SCMP) Receives New Patent for VTS-270
-
Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Jefferies 2017 Global Healthcare Conference
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of America Merrill Lynch 2017 Health Care Conference
-
Sucampo Reports First Quarter 2017 Financial Results
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank 42nd Annual Health Care Conference
-
Sucampo Announces First Quarter 2017 Earnings Call
-
Sucampo Pharma (SCMP) Confirms New Study Published in PLOS ONE Advances Science on VTS-270 for Treatment of Niemann-Pick Disease Type C1
-
New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1
-
Sucampo Pharma (SCMP) to Acquire Vtesse for $200M
-
Sucampo Acquires Vtesse Inc.
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 16th Annual Needham Healthcare Conference
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Oppenheimer 27th Annual Healthcare Conference
-
Sucampo Reports Fourth Quarter and Full Year 2016 Financial Results
-
Sucampo Announces Fourth Quarter and Full Year 2016 Earnings Call
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Global Healthcare Conference
-
Sucampo Reports Third Quarter 2016 Financial Results
-
Sucampo Announces Third Quarter 2016 Earnings Call
-
Sucampo Reports Second Quarter 2016 Financial Results
-
Paul Edick Joins Sucampo’s Board of Directors
-
Sucampo Announces Second Quarter 2016 Earnings Call
-
Sucampo Pharma (SCMP) to Discontinue Cobiprostone Development Following Phase 2a Results
-
Sucampo Provides Update on Cobiprostone Development Program
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Jefferies 2016 Healthcare Conference
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2016 UBS Global Healthcare Conference
-
Sucampo Reports Strong Results for First Quarter of 2016
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of America Merrill Lynch 2016 Healthcare Conference
-
Newest Release of Veeva Vault Streamlines Global Business Processes to Get Products to Market Faster and More Efficiently
-
Sucampo Standardizes on Veeva Vault for a Single Source of Truth Enterprise-wide
-
CORRECTING and REPLACING Sucampo Standardizes on Veeva Vault for a Single Source of Truth and Enterprise-wide Capability
-
Sucampo Announces First Quarter 2016 Earnings Call
-
Sucampo Pharma (SCMP) Phase 2a Study of Cobiprostone Missed Primary Endpoints
-
Sucampo Reports Top-Line Data from Phase 2a Study of Cobiprostone in Patients with PPI-Refractory Non-Erosive Reflux Disease (NERD) and Symptomatic Gastroesophageal Reflux Disease (sGERD)
-
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 28th Annual ROTH Conference
-
Sucampo Reports Continued Strong Performance for Fourth Quarter and Full Year 2015
-
Sucampo Announces Fourth Quarter and Full Year 2015 Earnings Call

